TABLE 1.

Model inputs.

Variable	Baseline value	Range	Distribution	Source
Survival
Weibull survival model for first-line chemotherapy
OS	Scale = 0.004716; shape = 1.533854	Fixed in DSA	Fixed in PSA	Estimated a
PFS	Scale = 0.003867; shape = 2.335407	Fixed in DSA	Fixed in PSA	Estimated a
HRs for first-line LY01008–chemotherapy vs. chemotherapy
OS	0.654	0.302–1.410	Normal	Estimated b
PFS	0.405	0.078–2.160	Normal	Estimated b
1-cycle probability of treatment discontinuation due to AEs
First-line LY01008 combined with chemotherapy	0.004298	0.002149–0.006448	Beta	Estimated c
First-line chemotherapy	0.006372	0.003186–0.009558	Beta	Estimated c
Costs (US$)
LY01008 price per 15 mg	24.99	12.49–37.48	Gamma	Local charge
Paclitaxel price per 175 mg	57.51	28.75–86.26	Gamma	Local charge
Carboplatin price per 6 mg	1.37	0.69–2.06	Gamma	Local charge
Nivolumab price per 4.5 mg	60.35	30.18–90.53	Gamma	Local charge
Routine follow-up cost per cycle	55.60	27.80–83.40	Gamma	[24]
Subsequent therapy cost per cycle	854.05	427.02–1,281.08	Gamma	[24]
BSC cost per cycle	337.50	168.75–506.25	Gamma	[24]
Palliative care cost per cycle	2,627.80	1,313.90–3,941.70	Gamma	[24]
AEs cost for LY01008 combined with chemotherapy	1,025.82	512.91–1,538.73	Gamma	Estimated d
AEs cost for chemotherapy	745.01	372.51–1,117.52	Gamma	Estimated d
Utilities
PFS health state	0.856	0.718–0.994	Beta	[29]
PD health state	0.768	0.595–0.941	Beta	[29]
Disutility for LY01008 combined with chemotherapy	0.061	0.031–0.092	Beta	Estimatedd
Disutility for chemotherapy	0.080	0.040–0.119	Beta	Estimatedd
Others
Discount rate (%)	5	0–8	Fixed in PSA	[22]
Patient weight (kg)	65	32.5–97.5	Normal	[27]
Body surface area (m2)	1.72	0.86–2.58	Normal	[27]
Creatinine clearance rate	70	35–105	Normal	[28]

OS, overall survival; PFS, progression-free survival; HR, hazard ratio; BSC, best supportive care; AEs: adverse events; PD, progressive disease.

^aEstimated by the survival fitting implemented in R software.

^bEstimated by the network meta-analysis implemented in R software.

^cEstimated in Supplementary Table S2.

^dEstimated in Supplementary Table S3.